Suchergebnisse - "Exemestane"

PubPharm (40)

1

Local-Regional Recurrence After Neoadjuvant Endocrine Therapy : Data from ACOSOG Z1031 (Alliance), a Randomized Phase 2 Neoadjuvant Comparison Between Letrozole, Anastrozole, and Exemestane for Postmenopausal Women with Estrogen Receptor-Positive Clinical Stage 2 or 3 Breast Cancer

enthalten in: Annals of surgical oncology | 2023

von Hunt, K. | Suman, V. | Wingate, H. | +6

2

Updates in hormone-receptor-positive, human epidermal growth factor receptor 2 (HER2)-negative advanced breast cancer in 2021

enthalten in: Bulletin du cancer | 2022

von Mezni, E. | Sabatier, R. | Goncalves, A. | +1

3

Differential biological effects of aromatase inhibitors : Apoptosis, autophagy, senescence and modulation of the hormonal status in breast cancer cells

enthalten in: Molecular and cellular endocrinology | 2021

von Augusto, T. | Amaral, C. | Almeida, C. | +2

4

A Prognostic Model Based on PAM50 and Clinical Variables (PAM50MET) for Metastatic Hormone Receptor-positive HER2-negative Breast Cancer

enthalten in: Clinical cancer research : an official journal of the American Association for Cancer Research | 2020

von Prat, A. | Tsai, Y. | Pascual, T. | +10

5

Overestimation of Late Distant Recurrences in High-Risk Patients With ER-Positive Breast Cancer : Validity and Accuracy of the CTS5 Risk Score in the TEAM and IDEAL Trials

enthalten in: Journal of clinical oncology : official journal of the American Society of Clinical Oncology | 2020

von Noordhoek, I. | Blok, E. | Meershoek-Klein Kranenbarg, E. | +15

CommentIn: J Clin Oncol. 2021 Feb 1;39(4):338-339. - PMID 33326252

6

Pyrotinib with trastuzumab and aromatase inhibitors as first-line treatment for HER2 positive and hormone receptor positive metastatic or locally advanced breast cancer : study protocol of a randomized controlled trial

enthalten in: BMC cancer | 2020

von Wang, C. | Lin, Y. | Zhou, Y. | +10

7

The NEOLETEXE trial : a neoadjuvant cross-over study exploring the lack of cross resistance between aromatase inhibitors

enthalten in: Future oncology (London, England) | 2019

von Bahrami, N. | Sauer, T. | Engebretsen, S. | +14

8

Endocrine treatment versus chemotherapy in postmenopausal women with hormone receptor-positive, HER2-negative, metastatic breast cancer : a systematic review and network meta-analysis

enthalten in: The Lancet. Oncology | 2019

von Giuliano, M. | Schettini, F. | Rognoni, C. | +16

CommentIn: Lancet Oncol. 2019 Oct;20(10):1329-1330. - PMID 31494036

9

Adjuvant anastrozole versus exemestane versus letrozole, upfront or after 2 years of tamoxifen, in endocrine-sensitive breast cancer (FATA-GIM3) : a randomised, phase 3 trial

enthalten in: The Lancet. Oncology | 2018

von De Placido, S. | Gallo, C. | De Laurentiis, M. | +128

CommentIn: Lancet Oncol. 2018 Apr;19(4):431-432. - PMID 29482984

10

Melasma treatment : A novel approach using a topical agent that contains an anti-estrogen and a vascular endothelial growth factor inhibitor

enthalten in: Medical hypotheses | 2017

von Cohen, P.